SUMMARY-We conducted a case-control study to search for any relationship between use of oral contraceptives and development of breast cancer or benign breast disease. Women less than 50 years old with these diseases were matched with 2 controls by age, race, religion, and hospital. Home interviews elicited information on oral contraceptive use and other host and environmental factors. The study population comprised 1,770 women, including 452 with breast cancer and 446 with benign breast disease. The relative risk of developing cancer or benign disease was measured by matched set and summary chi-square analyses. Although the relative risk of developing breast cancer among "ever-users" of oral contraceptives was 1.1, the risk among women using oral contraceptives for 2-4 years was 1.9 (significantly increased). This risk estimate reached 2.5 for the 2-to 4-year users if they were still taking oral contraceptives when entered into study. Moreover, prior biopsy for benign breast disease increased the cancer risk among long-term users by as much as ll-fold. The relative risk of breast cancer did not vary by age, interval since first use, earliest year of use, or interval since last use. These results could be interpreted to indicate that oral contraceptives did not induce breast cancer but may have accelerated the growth rate of preexisting breast cancer. The relative risk of developing benign breast disease among ever-users of oral contraceptives was 0.8 (significantly reduced); it decreased with longer duration of use until it reached 0.2 for women who took these hormones 8 years or more. The relative risk of benign breast disease was not affected by earliest year of use or interval since last use. We concluded that oral contraceptives reduced the incidence of benign breast disease, but that use of steroid hormones is iii-adVised for women with already established benign breast disease.-J Natl Cancer Inst 55: [767] [768] [769] [770] [771] [772] [773] 1975 .
The wide-scale acceptance and long-term usage of oral contraceptives continue to arouse concern over adverse effects they may have. This is especially so in regard to any possible relationship between use of oral contraceptives and carcinogenesis, either through acceleration of growth of preexisting cancers or initiation or promotion of cancer occurrence. Although early observations deny any relationship between oral contraceptives use and human breast malignancy (1) (2) (3) (4) , and even suggest a sparing effect on benign breast disease (2, 3) [a recognized risk factor of breast cancer (5) ], continued surveillance for carcinogenesis from these potent steroid hormones is indicated.
In 1970, we undertook a study of oral contraceptives as related to risk of breast disease, either malignant or benign. This was about 10 years after oral contraceptives first became available and some 6 years after they became widely used. Although perhaps too short a time has passed to demonstrate any cancer induction or even promotion, the time might be sufficient to demonstrate accelerated growth of previously unrecognized tumors or altered incidence of benign breast disease. We report here on a 3-year case-control study of 1,770 women from the San Francisco Bay Area interviewed for their history of oral contraceptive use and other host and environmental characteristics that might relate to either benign or malignant disease of the breast.
MATERIALS AND METHODS
Study subjects were women 49 years of age or younger, who had been admitted to one of 19 San Francisco Bay Area hospitals with newly diagnosed breast cancer, and women with benign, noninflammatory breast lesions, who were matched to the cancer patients by religion (Catholic, non-Catholic, and unspecified), race (white and black), age (5-yr age groups), hospital, and time of hospitalization (within 7 mo). As controls, 2 other patients, one from a medical and the other from a surgical service, were matched to each case subject on the same variables. Excluded from study were nonresidents of the area, patients admitted to obstetric or gynecologic services, those hospitalized for phlebothrombotic disorders or mental disease, and those who had undergone a sterilizing operation before 1960. The distribution of discharge diagnoses of disease among medical and surgical control patients is given in table 1. Case identification was continued for 3 years to include breast cancer patients admitted to a hospital between January I, 1970, and December 31, 1972.
After they left the hospital, study subjects were questioned by pre trained nurse interviewers who collected detailed information concerning each subject'S contraceptive practices, menstrual and obstetric experiences, hormone use, medical and surgical history with special attention to operations on the breast and female organs, and family history of breast cancer. When necessary, supplemental information was obtained from attending physicians or hospital records. A pathologist reviewed all breast tissue sections for verification of diagnoses and uniform classification of benign lesions. Benign lesions were subdivided into fibroadenoma, fibrocystic disease (active or inactive), adenosis, intraductal papilloma, and "other."
The method of matching permitted comparison of the same control patients with both breast cancer and benign disease patients. Statistical significance was tested by matched set analyses (6, 7) , and estimates of relative risk of disease associated with use of oral contraceptives were computed. Matched case-control pairs and case-control triples were analyzed separately (the latter with both medical and surgical controls). Because there was little difference, only the analyses of the matched triples are presented here. To adjust for confounding variables known to be associated with both oral contraceptive use and incidence of breast disease, the data were reanalyzed by the summary chi-square procedure of Mantel and Haenszel (8) . In that procedure, adjustments were always made for differences in race, religion, and age at admission to hospital. As indicated later, adjustments sometimes were made also for educational level of the patient, menopausal status, and evidence of prior benign breast disease. In all instances the risk of breast disease compared women who used oral contraceptives with women who did not.
RESULTS
A total of 1,770 women were included for study: 452 with breast cancer, 446 with benign breast disease, 433 with other medical conditions, and 439 with other surgical conditions. There were 421 complete triples for study of breast cancer and 420 for study of benign breast disease.
The distribution of selected characteristics thought to be related to the development of breast disease and on which case and control subjects had not been matched is shown in table 2. As compared with combined medical and surgical controls, breast cancer patients were better educated and their husbands were more apt to be in professional or managerial positions. They were older at the time a first child was born, were less apt to be menopausal, had a greater frequency of prior benign breast disease (as indicated by biopsy), and were more likely to have had mothers who developed breast cancer. Also, they had a mean weight of 6 pounds less but were of the same mean height as control subjects 2 years before entering the study.
When benign breast disease patients were compared with the same combined control patients, the former were less frequently menopausal, had experienced a higher incidence of prior benign breast disease, and, like cancer patients, weighed less for their height than did control subjects 2 years before entering the study.
The demonstrated associations conform largely to previously established findings concerning risk factors of breast disease, except for the rather marked lower body weight among case subjects as compared with controls. This may be an artifact of study design, the leaner women being better able to palpate existing bre.ast masses, or controls being heavier for their height because of their illnesses.
Of the characteristics distributed differently among case and control subjects, education (an index of social class), menopausal status, and previous breast tissue biopsy (an index of previous benign breast disease) also were associated independently with use of oral contraceptives. Therefore, we adjusted for these characteristics in some of the analyses.
The four tables that follow give an overview of frequency and duration of oral contraceptive use among subjects. Frequency of "ever-use," irrespective of duration (table 3) varied with age and race. The proportion of users was highest in the young, averaging 86% in those less than 30 years of age, 66% in subjects aged 30-39, and 39% in those aged 40-49 years. All black women less than 30 years had at some time used oral contraceptives, but the practice decreased more rapidly with age among black as compared with white women. Mean age at first use was similar in breast disease patients and controls but was consistently lower in black subjects. Altogether, 45% of study subjects had been on oral contraceptives at some time, and the proportion of ever-users was lowest among the benign breast disease patients. Table 3 also gives proportions of oral contraceptive users among subjects by the three religion categories used in matching. As expected, oral contraceptives were taken less frequently by women who declared themselves Roman Catholics. The practice was most common among those for whom information on religion was either not given or not recorded.
The frequency of current use of oral contraceptives (use within 1 mo of hospital admission) is shown in table 4. As for ever-users, the proportion of current users was highest for youngest women and declined steadily with age. Current users represented 16% of patients with breast cancer, a percentage similar to the 13% of combined medical and surgical control patients. However, a smaller proportion (9%) of patients with benign breast disease were taking steroid hormones within the month preceding hospital admission than were the combined controls. Table 5 gives data on duration of oral contraceptive use. Approximately half of the study population had been on oral contraceptives for 2 years or less, and for only 15% did duration exceed 6 years. Patients with • Sets in which the case and both control subjects are nonusers of OC appear in each subgroup of classifications 2-6. Thus the total of subgroups may exceed the number of sets.
• Nonusers of OC appear in each subgroup of classifications 2-6. , Adjusted for differences in race, religion, and age at hospital admission (matching factors).
• Adjusted for differences in education, menopause, and previous breast biopsy, In addition to factors listed in footnots '.
benign breast disease were an exception to this general pattern. They had a higher proportion of short-term users (59% on oral contraceptives 2 years or less) and a corresponding deficit of long-term users (9% exceeding 6 years). Total duration of oral contraceptive use for breast cancer and benign breast disease patients and their matched controls is shown in table 6. Although the total person-months of use were similar for cancer patients and their matched controls (mean durations of 16.8 and 16.3, respectively), they differed markedly between benign breast disease patients and their matched controls (mean durations of 10.3 and 16.6 mo). Table 7 gives estimates for relative risk of developing breast cancer associated with oral contraceptives. Findings are based both on matched set and summary chisquare analyses. A relative risk of 1.0 indicates that the estimated incidence of disease is the same among subjects who used oral contraceptives and among subjects who did not. A relative risk of 1.2 indicates a 20% increased disease incidence among the users of oral contraceptives.
Ever-use was examined in three age groups. Since the practice was universally high among women under 30 years of age, there were not enough discordant sets to allow calculation of relative risk estimates for them. Relative risks in older age groups were close to unity, and the relative risk for all ages was 1.1. Adjustments for educational level, menopausal status, and history of prior breast tissue biopsy did not affect the overall relative risk.
The effect of duration of use was examined for periods of within 2 years, 2-4 years, 4-8 years, or more than 8 years. There was a nearly twofold increased relative risk of breast cancer when oral contraceptives were used for a minimum of 2 years and a maximum of 4 years. This held for both types of statistical analysis. For all other durations, risks were within the range of chance variation and showed no consistent trends.
Use as defined in these analyses did not denote continuity. We therefore repeated the analyses for continuous users. Results were similar to those just cited, with relative risks of 1.0 for periods of within 2 years, 2.1 for 2-4 years, and 1.1 for more than 4 years. Again, only for the duration of 2-4 years was the association statistically significant (p<0.01).
Interval between first oral contraceptive use and hospital admission, examined for periods within 3 years, 3-6 years, or over 6 years, did not seem to affect estimates of relative risk of breast cancer.
We examined temporal trends for differences that might correspond to major dosage changes in the composition of oral contraceptives. Users were divided into three groups, by first use in 1960-64 (high progestogen, high estrogen dosage), 1965-69 (low progestogen, high estrogen), or 1970 and later (low progestogen, low estrogen dosage). There was no indication that relative risks differed among the three groups.
Subjects who had stopped oral contraceptives 2 months or more before admission (past users) were subclassified according to length of interval since stopping (within 1 yr, 1-3 yr, or 3 yr or more). In none of the three intervals did the relative risk of breast cancer differ significantly from unity.
To determine whether oral contraceptive use of 2-4 years increased breast cancer risk selectively, we then examined the effect of duration of use among subjects who had been on oral contraceptives to within 1 month of admission to hospital. There were 133 sets of triples who were current users. In both matched triples and summary chi-square analyses, the overall relative risk of breast cancer was increased (1.3 and 1.5, respectively). Although the subdivision of current users by duration of use resulted in small numbers, use of oral contraceptives for up to 5 years clearly was associated with an increased relative risk; and relative risk again decreased when duration of use was 5 years or longer. The 2.5-fold relative risk estimate for 2-4 years' use in the summary chi-square analysis (p=0.04) is based on 16 cancer patients, 10 of whom were continuous users. Table 8 shows relative risk of breast cancer, by duration of oral contraceptive use, for women who gave a history of prior biopsy for benign breast disease and for those who did not. Among ever-users, cancer risk tended to be greater for women with prior benign breast disease (1.5), the risk being significantly greater for women who had been on oral contraceptives for more than 6 years (11.2). Moreover, among current users, cancer risk was increased nearly sevenfold. Among women without a history of prior biopsy for benign breast disease, the increased risk associated with 2-4 years' use reappeared, both for ever-users and current users. Table 9 shows estimates of relative risk of developing benign breast disease in relation to oral contraceptive use. The relative risk of benign disease from ever-using oral contraceptives was 0.8 as based on the matched set analysis, and the association was of borderline significance (P=0.05). Adjustment for educational level, menopausal status, and previous breast biopsy in the summary chi-square analysis yielded the same relative risk estimate for all ages, and little change by specific age groups.
Duration of oral contraceptive use and relative risk of benign breast disease were inversely related. From a value of 0.9 for women on oral contraceptives up to 2 years, relative risk decreased to 0.6 for users for 2-4 years, 0.5 for those for 5-8 years, and 0.2 for long-term users (8 yr and over). The summary chi-square analysis adjusted for differences in education, menopause, and prior breast tissue biopsy resulted in relative risks of 1.0, 0.9, 0.6, and 0.4, respectively, the difference being statistically significant for duration of use over 4 years. Relative risk by interval between first use and hospital admission was significantly reduced for intervals of 6 or more years, which reflected a long duration of use.
Relative risk was not affected appreciably or consistently when users were subdivided by first use in one of three time periods in which the composition of oral con- • Based on summary chi-square analyses and adjusted for differences in race, rehgion, age at hospital admission, education, and menopause.
• Adjusted for differences m biopsy, in addition to factors listed in footnote G. traceptive preparations differed. As for interval since last use, past users who had stopped oral contraceptives at varying intervals before admission showed no difference in relative risk. However, for current users, a significantly reduced relative risk resulted, risks again decreasing with increasing duration of oral contraceptive use.
DISCUSSION
The results of the present case-control study of San Francisco Bay Area women less than 50 years of age are consistent with, and extend, findings reported for both British (2, 3, 9) and American (1, (10) (11) (12) women. Analyzing the experience of over 450 breast cancer patients and nearly double the number of control patients, we found little evidence that oral contraceptives induced breast cancer. However, two findings were puzzling: I) An increased breast cancer risk was associated with oral contraceptive use of not less than 2 or more than 4 years; and 2) breast cancer risk was increased substantially for longterm users (6 or more yr) who had experienced a prior biopsy for benign breast disease.
The twofold increased risk among users for 2-4 years pertains to both ever-users and current users after adjustment was made for the confounding factors of educational level, menopausal status, and history of prior breast tissue biopsy, in addition to factors of race, religion, and age. The finding of this added risk may be due simply to chance. An alternate explanation is that oral contraceptives accelerate the growth rate of preexisting subclinical malignant lesions, with these lesions reaching the level of clinical recognition only after 2 years of drug usage and all being diagnosed within 2 additional years.
The excess risk of breast cancer (6-to II-fold) among women with history of prior breast tissue biopsy suggests that some have a potential for cancer that is activated by long sustained oral contraceptive use (6 or more yr Other studies showed estimated relative risks of breast cancer associated with oral contraceptive use to be less than one. However, the present study with much larger numbers yielded estimates slightly greater than one, which may be explained by the two curious findings just discussed. Although this tendency toward added risk may represent a bias due to earlier detection of breast cancer because of greater alertness to it among women on oral contraceptives, it may, on the other hand, anticipate a true increase in risk.
Present findings prompt continued surveillance of oral contraceptive usage for any carcinogenic effect. We must remember that during the period encompassed by this study, these drugs had been available for a maximum of 12 years, perhaps a period too short to induce or promote breast cancer but sufficient to enhance the growth of preexisting cancer. Also, the findings provide no information on women much past the reproductive age and only limited data on young women. In the young, oral contraceptive use has become almost universal, a fact that may preclude future comparison of users with nonusers in such populations.
Some of these limitations apply equally to study of benign breast disease. Patients with such disease were chosen to match the ages of breast cancer patients and thus are somewhat older than the universe of patients from which they truly come. Also, the study design ex-cludes women with benign breast disease who were 50 years of age and over. Nevertheless, as described by others, present findings imply that oral contraceptive users are less apt to develop benign breast disease than nonusers. The observed reduction in risk approximated 20%. Moreover, in California women observed for up to 12 years since oral contraceptives became available, there was a progressive deficit of disease with increasing duration of use.
Since benign breast disease per se predisposes to breast cancer, surveillance for long-term oncogenic effects of oral contraceptives should include extended observations on any association of type-specific benign disease with use of these hormones.
